{"title":"成为 CA 的新编辑:未来就是现在","authors":"Don S. Dizon MD","doi":"10.3322/caac.21828","DOIUrl":null,"url":null,"abstract":"<p><i>CA: A Cancer Journal for Clinicians (CA)</i> was not a journal I ever saw myself publishing in let alone leading; its impact factor and prestige seemed out of reach for me—such is the Imposter Syndrome. Still, I came across the opportunity to become its editor and I applied, thinking I would regret it if I did not at least try. To my delight, I was chosen to succeed Ted Gansler, who had led <i>CA</i> as its editor for 23 years. Unbeknownst to me, I would also be the first to lead the journal from outside of the American Cancer Society (ACS).</p><p><i>CA</i> holds a special place in medicine, and specifically in oncology. Best known for the annual publication of Cancer Statistics, it is also the reference for a diverse readership, from primary care providers to advanced practice practitioners, both within the United States and globally. Therefore, it remains important that what we publish is accessible to all—regardless of whether they are specialized in cancer medicine. With that in mind, we have instituted new instructions for our potential authors, and they are based in intentionality. Articles submitted need to be understandable to our audience, and this is an opportunity to translate technical concepts into much more accessible language. I’ve asked the authors to be cognizant that our readership includes not only diverse health professionals but also people who themselves have experienced cancer, their caregivers, and advocates. As such, patient-centric language should be used. As examples, cancer should not be used as an adjective (e.g., breast cancer patients) nor should progression on treatment be referred to as a failure. The patient experience is also one that it is important to acknowledge, and I have challenged those who intend to submit to <i>CA</i> to incorporate patients’ points of view in the construction and the writing of articles and to include them as authors wherever it makes sense.</p><p>As we move into the future, I hope to make use of <i>CA</i> to democratize the access to important information; and, in 2024, <i>CA</i> will begin considering publication of high-impact clinical trial results. I intend the process to be a collaboration from the start, from gaging the appropriateness of phase 3 research for <i>CA</i> to timely peer review and publication, while maintaining the standards set above. Although this is a major shift in the past content <i>CA</i> has accepted, our editorial group at ACS believe this is an important step for <i>CA</i>, not only because of its eminence in medical publishing but because it represents an opportunity for everyone to access information that may change the standards of care. These articles will not be restricted—they will be free and downloadable at our journal’s website, just as <i>CA</i> content has always been.</p><p>Most of all, I want to ensure all who read and contribute to <i>CA</i> that the rigorous care that Dr. Gansler provided will continue. Articles are personally reviewed by me before formal submission and peer review. This is not meant to be onerous but to ensure that consistency and quality in writing are reflected in our journal, adhering to the direction we have set forth above.</p><p>It has been a great first year at <i>CA</i>, and I hope that, in small ways and some larger ones, it will continue to be a source for all interested in oncology—from prevention to treatment to survivorship and palliative care. This is the flagship journal of the ACS; and, as we look forward, we will bear this in mind in all that we publish and ensure that the progress in oncology is shared. With everyone.</p><p>With best regards,</p><p>Don S. Dizon, MD</p><p>Editor, <i>CA: A Cancer Journal for Clinicians</i></p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":null,"pages":null},"PeriodicalIF":503.1000,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21828","citationCount":"0","resultStr":"{\"title\":\"Becoming the new editor for CA: The future is now\",\"authors\":\"Don S. Dizon MD\",\"doi\":\"10.3322/caac.21828\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><i>CA: A Cancer Journal for Clinicians (CA)</i> was not a journal I ever saw myself publishing in let alone leading; its impact factor and prestige seemed out of reach for me—such is the Imposter Syndrome. Still, I came across the opportunity to become its editor and I applied, thinking I would regret it if I did not at least try. To my delight, I was chosen to succeed Ted Gansler, who had led <i>CA</i> as its editor for 23 years. Unbeknownst to me, I would also be the first to lead the journal from outside of the American Cancer Society (ACS).</p><p><i>CA</i> holds a special place in medicine, and specifically in oncology. Best known for the annual publication of Cancer Statistics, it is also the reference for a diverse readership, from primary care providers to advanced practice practitioners, both within the United States and globally. Therefore, it remains important that what we publish is accessible to all—regardless of whether they are specialized in cancer medicine. With that in mind, we have instituted new instructions for our potential authors, and they are based in intentionality. Articles submitted need to be understandable to our audience, and this is an opportunity to translate technical concepts into much more accessible language. I’ve asked the authors to be cognizant that our readership includes not only diverse health professionals but also people who themselves have experienced cancer, their caregivers, and advocates. As such, patient-centric language should be used. As examples, cancer should not be used as an adjective (e.g., breast cancer patients) nor should progression on treatment be referred to as a failure. The patient experience is also one that it is important to acknowledge, and I have challenged those who intend to submit to <i>CA</i> to incorporate patients’ points of view in the construction and the writing of articles and to include them as authors wherever it makes sense.</p><p>As we move into the future, I hope to make use of <i>CA</i> to democratize the access to important information; and, in 2024, <i>CA</i> will begin considering publication of high-impact clinical trial results. I intend the process to be a collaboration from the start, from gaging the appropriateness of phase 3 research for <i>CA</i> to timely peer review and publication, while maintaining the standards set above. Although this is a major shift in the past content <i>CA</i> has accepted, our editorial group at ACS believe this is an important step for <i>CA</i>, not only because of its eminence in medical publishing but because it represents an opportunity for everyone to access information that may change the standards of care. These articles will not be restricted—they will be free and downloadable at our journal’s website, just as <i>CA</i> content has always been.</p><p>Most of all, I want to ensure all who read and contribute to <i>CA</i> that the rigorous care that Dr. Gansler provided will continue. Articles are personally reviewed by me before formal submission and peer review. This is not meant to be onerous but to ensure that consistency and quality in writing are reflected in our journal, adhering to the direction we have set forth above.</p><p>It has been a great first year at <i>CA</i>, and I hope that, in small ways and some larger ones, it will continue to be a source for all interested in oncology—from prevention to treatment to survivorship and palliative care. This is the flagship journal of the ACS; and, as we look forward, we will bear this in mind in all that we publish and ensure that the progress in oncology is shared. With everyone.</p><p>With best regards,</p><p>Don S. Dizon, MD</p><p>Editor, <i>CA: A Cancer Journal for Clinicians</i></p>\",\"PeriodicalId\":137,\"journal\":{\"name\":\"CA: A Cancer Journal for Clinicians\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":503.1000,\"publicationDate\":\"2024-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21828\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CA: A Cancer Journal for Clinicians\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.3322/caac.21828\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21828","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
CA: A Cancer Journal for Clinicians》(《CA:临床医生癌症杂志》)并不是一本我认为自己能发表文章的杂志,更不用说领导了;它的影响因子和声望对我来说似乎遥不可及--这就是 "冒名顶替综合症"。不过,我还是得到了担任该杂志编辑的机会,于是我就申请了,心想如果不至少试一试,我会后悔的。令我欣喜的是,我被选中接替泰德-甘斯勒(Ted Gansler),他曾担任《CA》编辑长达 23 年。我并不知道,我也将是第一位在美国癌症协会(ACS)之外领导该杂志的人。《癌症》在医学,特别是肿瘤学中占有特殊的地位。美国癌症协会》因每年出版《癌症统计》而闻名,同时也是美国和全球从初级保健提供者到高级执业医师等不同读者群的参考资料。因此,重要的是,我们出版的内容要让所有人都能阅读,无论他们是否是癌症医学专业人员。有鉴于此,我们为潜在作者制定了新的指导原则,这些原则都是有目的性的。所提交的文章必须能为读者所理解,这是一个将技术概念转化为更通俗易懂的语言的机会。我要求作者们认识到,我们的读者群不仅包括各类医疗专业人士,还包括亲身经历过癌症的患者、他们的护理人员和倡导者。因此,应该使用以患者为中心的语言。例如,不应将癌症用作形容词(如乳腺癌患者),也不应将治疗进展称为失败。患者的经历也是必须承认的一点,我已经向那些打算向CA投稿的人提出挑战,要求他们在构思和撰写文章时纳入患者的观点,并在合理的情况下将患者列为作者。我希望这个过程从一开始就是一个合作的过程,从评估第 3 期研究是否适合 CA,到及时进行同行评审和发表,同时保持上述标准。虽然这与 CA 过去接受的内容有很大的不同,但我们 ACS 的编辑团队认为这对 CA 来说是重要的一步,这不仅是因为 CA 在医学出版界的声望,还因为这代表着每个人都有机会获取可能会改变医疗标准的信息。最重要的是,我希望向所有阅读和投稿《CA》的读者保证,甘斯勒医生提供的严谨医疗服务将继续下去。在正式投稿和同行评审之前,我将亲自审阅文章。这并不意味着繁琐,而是为了确保我们的期刊能体现出写作的一致性和质量,坚持我们上面提出的方向。在《CA》的第一年是非常美好的一年,我希望它能在一些小的方面和一些大的方面继续成为所有对肿瘤学感兴趣的人的源泉--从预防到治疗,再到生存和姑息治疗。这是美国癌症协会的旗舰期刊;展望未来,我们将在所有的出版工作中牢记这一点,确保肿瘤学的进步得到共享。向大家致以最崇高的敬意!Don S. Dizon,医学博士《CA.A Cancer Journal for Clinicians》编辑:临床医生癌症杂志
CA: A Cancer Journal for Clinicians (CA) was not a journal I ever saw myself publishing in let alone leading; its impact factor and prestige seemed out of reach for me—such is the Imposter Syndrome. Still, I came across the opportunity to become its editor and I applied, thinking I would regret it if I did not at least try. To my delight, I was chosen to succeed Ted Gansler, who had led CA as its editor for 23 years. Unbeknownst to me, I would also be the first to lead the journal from outside of the American Cancer Society (ACS).
CA holds a special place in medicine, and specifically in oncology. Best known for the annual publication of Cancer Statistics, it is also the reference for a diverse readership, from primary care providers to advanced practice practitioners, both within the United States and globally. Therefore, it remains important that what we publish is accessible to all—regardless of whether they are specialized in cancer medicine. With that in mind, we have instituted new instructions for our potential authors, and they are based in intentionality. Articles submitted need to be understandable to our audience, and this is an opportunity to translate technical concepts into much more accessible language. I’ve asked the authors to be cognizant that our readership includes not only diverse health professionals but also people who themselves have experienced cancer, their caregivers, and advocates. As such, patient-centric language should be used. As examples, cancer should not be used as an adjective (e.g., breast cancer patients) nor should progression on treatment be referred to as a failure. The patient experience is also one that it is important to acknowledge, and I have challenged those who intend to submit to CA to incorporate patients’ points of view in the construction and the writing of articles and to include them as authors wherever it makes sense.
As we move into the future, I hope to make use of CA to democratize the access to important information; and, in 2024, CA will begin considering publication of high-impact clinical trial results. I intend the process to be a collaboration from the start, from gaging the appropriateness of phase 3 research for CA to timely peer review and publication, while maintaining the standards set above. Although this is a major shift in the past content CA has accepted, our editorial group at ACS believe this is an important step for CA, not only because of its eminence in medical publishing but because it represents an opportunity for everyone to access information that may change the standards of care. These articles will not be restricted—they will be free and downloadable at our journal’s website, just as CA content has always been.
Most of all, I want to ensure all who read and contribute to CA that the rigorous care that Dr. Gansler provided will continue. Articles are personally reviewed by me before formal submission and peer review. This is not meant to be onerous but to ensure that consistency and quality in writing are reflected in our journal, adhering to the direction we have set forth above.
It has been a great first year at CA, and I hope that, in small ways and some larger ones, it will continue to be a source for all interested in oncology—from prevention to treatment to survivorship and palliative care. This is the flagship journal of the ACS; and, as we look forward, we will bear this in mind in all that we publish and ensure that the progress in oncology is shared. With everyone.
期刊介绍:
CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.